Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.
Identifieur interne : 000333 ( Main/Exploration ); précédent : 000332; suivant : 000334Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.
Auteurs : Cicely Kerr [Royaume-Uni] ; Emily J. Lloyd [Royaume-Uni] ; Charlotte E. Kosmas [Royaume-Uni] ; Helen T. Smith [Royaume-Uni] ; James A. Cooper [Royaume-Uni] ; Karissa Johnston [Canada] ; Emma Mcintosh [Royaume-Uni] ; Andrew J. Lloyd [Royaume-Uni]Source :
- Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [ 1573-2649 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Choice Behavior, Female, France, Humans, Italy, Levodopa (pharmacokinetics), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Quality of Life (psychology), Spain, Surveys and Questionnaires, United Kingdom.
- MESH :
- chemical , pharmacokinetics : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease, Quality of Life.
- Adult, Aged, Choice Behavior, Female, France, Humans, Italy, Male, Middle Aged, Spain, Surveys and Questionnaires, United Kingdom.
Abstract
Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of 'off time' resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson's (PwP).
DOI: 10.1007/s11136-015-1187-0
PubMed: 26627224
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000228
- to stream PubMed, to step Curation: 000228
- to stream PubMed, to step Checkpoint: 000228
- to stream Ncbi, to step Merge: 001D91
- to stream Ncbi, to step Curation: 001D91
- to stream Ncbi, to step Checkpoint: 001D91
- to stream Main, to step Merge: 000334
- to stream Main, to step Curation: 000333
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.</title><author><name sortKey="Kerr, Cicely" sort="Kerr, Cicely" uniqKey="Kerr C" first="Cicely" last="Kerr">Cicely Kerr</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Lloyd, Emily J" sort="Lloyd, Emily J" uniqKey="Lloyd E" first="Emily J" last="Lloyd">Emily J. Lloyd</name><affiliation wicri:level="1"><nlm:affiliation>ViiV Healthcare, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ViiV Healthcare, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Kosmas, Charlotte E" sort="Kosmas, Charlotte E" uniqKey="Kosmas C" first="Charlotte E" last="Kosmas">Charlotte E. Kosmas</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Smith, Helen T" sort="Smith, Helen T" uniqKey="Smith H" first="Helen T" last="Smith">Helen T. Smith</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, James A" sort="Cooper, James A" uniqKey="Cooper J" first="James A" last="Cooper">James A. Cooper</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Johnston, Karissa" sort="Johnston, Karissa" uniqKey="Johnston K" first="Karissa" last="Johnston">Karissa Johnston</name><affiliation wicri:level="1"><nlm:affiliation>ICON Epidemiology, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ICON Epidemiology, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Mcintosh, Emma" sort="Mcintosh, Emma" uniqKey="Mcintosh E" first="Emma" last="Mcintosh">Emma Mcintosh</name><affiliation wicri:level="4"><nlm:affiliation>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Lloyd, Andrew J" sort="Lloyd, Andrew J" uniqKey="Lloyd A" first="Andrew J" last="Lloyd">Andrew J. Lloyd</name><affiliation wicri:level="3"><nlm:affiliation>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford, UK. Andrew@bladonassoc.com.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26627224</idno><idno type="pmid">26627224</idno><idno type="doi">10.1007/s11136-015-1187-0</idno><idno type="wicri:Area/PubMed/Corpus">000228</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000228</idno><idno type="wicri:Area/PubMed/Curation">000228</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000228</idno><idno type="wicri:Area/PubMed/Checkpoint">000228</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000228</idno><idno type="wicri:Area/Ncbi/Merge">001D91</idno><idno type="wicri:Area/Ncbi/Curation">001D91</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D91</idno><idno type="wicri:Area/Main/Merge">000334</idno><idno type="wicri:Area/Main/Curation">000333</idno><idno type="wicri:Area/Main/Exploration">000333</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.</title><author><name sortKey="Kerr, Cicely" sort="Kerr, Cicely" uniqKey="Kerr C" first="Cicely" last="Kerr">Cicely Kerr</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Lloyd, Emily J" sort="Lloyd, Emily J" uniqKey="Lloyd E" first="Emily J" last="Lloyd">Emily J. Lloyd</name><affiliation wicri:level="1"><nlm:affiliation>ViiV Healthcare, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ViiV Healthcare, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Kosmas, Charlotte E" sort="Kosmas, Charlotte E" uniqKey="Kosmas C" first="Charlotte E" last="Kosmas">Charlotte E. Kosmas</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Smith, Helen T" sort="Smith, Helen T" uniqKey="Smith H" first="Helen T" last="Smith">Helen T. Smith</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, James A" sort="Cooper, James A" uniqKey="Cooper J" first="James A" last="Cooper">James A. Cooper</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Johnston, Karissa" sort="Johnston, Karissa" uniqKey="Johnston K" first="Karissa" last="Johnston">Karissa Johnston</name><affiliation wicri:level="1"><nlm:affiliation>ICON Epidemiology, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ICON Epidemiology, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Mcintosh, Emma" sort="Mcintosh, Emma" uniqKey="Mcintosh E" first="Emma" last="Mcintosh">Emma Mcintosh</name><affiliation wicri:level="4"><nlm:affiliation>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Lloyd, Andrew J" sort="Lloyd, Andrew J" uniqKey="Lloyd A" first="Andrew J" last="Lloyd">Andrew J. Lloyd</name><affiliation wicri:level="3"><nlm:affiliation>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford, UK. Andrew@bladonassoc.com.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author></analytic><series><title level="j">Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</title><idno type="eISSN">1573-2649</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Choice Behavior</term><term>Female</term><term>France</term><term>Humans</term><term>Italy</term><term>Levodopa (pharmacokinetics)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Quality of Life (psychology)</term><term>Spain</term><term>Surveys and Questionnaires</term><term>United Kingdom</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Choice Behavior</term><term>Female</term><term>France</term><term>Humans</term><term>Italy</term><term>Male</term><term>Middle Aged</term><term>Spain</term><term>Surveys and Questionnaires</term><term>United Kingdom</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of 'off time' resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson's (PwP).</div></front></TEI><affiliations><list><country><li>Canada</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Oxfordshire</li><li>Écosse</li></region><settlement><li>Glasgow</li><li>Oxford</li></settlement><orgName><li>Université de Glasgow</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Kerr, Cicely" sort="Kerr, Cicely" uniqKey="Kerr C" first="Cicely" last="Kerr">Cicely Kerr</name></region><name sortKey="Cooper, James A" sort="Cooper, James A" uniqKey="Cooper J" first="James A" last="Cooper">James A. Cooper</name><name sortKey="Kosmas, Charlotte E" sort="Kosmas, Charlotte E" uniqKey="Kosmas C" first="Charlotte E" last="Kosmas">Charlotte E. Kosmas</name><name sortKey="Lloyd, Andrew J" sort="Lloyd, Andrew J" uniqKey="Lloyd A" first="Andrew J" last="Lloyd">Andrew J. Lloyd</name><name sortKey="Lloyd, Emily J" sort="Lloyd, Emily J" uniqKey="Lloyd E" first="Emily J" last="Lloyd">Emily J. Lloyd</name><name sortKey="Mcintosh, Emma" sort="Mcintosh, Emma" uniqKey="Mcintosh E" first="Emma" last="Mcintosh">Emma Mcintosh</name><name sortKey="Smith, Helen T" sort="Smith, Helen T" uniqKey="Smith H" first="Helen T" last="Smith">Helen T. Smith</name></country><country name="Canada"><noRegion><name sortKey="Johnston, Karissa" sort="Johnston, Karissa" uniqKey="Johnston K" first="Karissa" last="Johnston">Karissa Johnston</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000333 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000333 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26627224
|texte= Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26627224" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |